Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. (4th March 2019)

• Record Type: Journal Article
• Authors: Meysami, Parisa; Rezaei, Farhad; Marashi, Sayed Mahdi; Amiri, Mohammad Mehdi; Bakker, Emyr; Mokhtari-Azad, Talat
• Is Part Of: Future virology. Volume 14:Number 3(2019)
• Page Start: 139
• Page End: 152
• Publication Date: 2019-03-04
• Subjects: anti-HER2 scFv -- Apoptin -- baculovirus surface display -- breast cancer; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl-2018-0187
• Languages: English
• ISSNs: 1746-0794

Abstract

Aim: Since HER2 targeted therapies have shown clinical benefit in breast cancer, in the present study recombinant baculovirus (BV) displaying anti-HER2 single-chain variable domain fragment (scFv) expressing Apoptin was generated.Methods: The binding specificity and surface display of anti-HER2 scFv were evaluated using enzyme-linked immunosorbent assay (ELISA) and electron microscopy, respectively. The targeting properties and cytotoxic effect on breast cancer cells determined by fluorescence microscopy and MTT assays.Results: The results demonstrated that recombinant BV could specifically bind to HER2-overexpressing SK-BR-3 cells but not to the HER2 negative MCF-7 cells and reduced the viability of SK-BR-3 cells by expressing Apoptin.Conclusion: These results suggest that the antitumor effect of Apoptin in combination with HER2 targeting of this recombinant BV makes it a promising vector in targeted cancer therapy.